Showing results (1211-1220 of 1,423) with videos related to

Sort By:
Pageof 143
British Journal of Haematology|October 20, 2022
A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusionsTing Zhou, Constance M Yuan, Kathryn Lurain, et al.
Psychosomatic Medicine|August 30, 2008
Nighttime heart rate and survival in depressed patients post acute myocardial infarctionRobert M Carney, Brian Steinmeyer, Kenneth E Freedland, et al.
European Heart Journal. Acute Cardiovascular Care|February 23, 2021
Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on ThrombosisKonstantin A Krychtiuk, Walter S Speidl, Evangelos Giannitsis, et al.
Journal of the American College of Cardiology|November 3, 2022
Implementation of High-Sensitivity Cardiac Troponin Assays in the United StatesCian McCarthy, Shuang Li, Tracy Y Wang, et al.
Oncotarget|June 2, 2016
The genetic landscape of dural marginal zone lymphomasKarthik A Ganapathi, Vaidehi Jobanputra, Fabio Iwamoto, et al.
Clinical Transplantation|January 6, 2025
Second Time Around: Increased Rate of Living Donation From Repeat Organ DonorsCarolyn N Sidoti, Kelly Terlizzi, Conor Donnelly, et al.
Blood|March 7, 2009
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationOla Landgren, Ethel S Gilbert, J Douglas Rizzo, et al.
Blood|September 7, 2013
Indolent T-cell lymphoproliferative disease of the gastrointestinal tractAnamarija M Perry, Roger A Warnke, Qinglong Hu, et al.
The Lancet. Haematology|April 3, 2023
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trialChristopher Melani, Kennichi Dowdell, Stefania Pittaluga, et al.
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.
Pageof 143